Modeling cortical cataractogenesis: IX. Activity of vitamin E and esters in preventing cataracts and gamma-crystallin leakage from lenses in diabetic rats.
Normal and streptozotocin diabetic female Wistar rats were given vitamin E in the diet as the tocopherol, acetate, or succinate form (2,850 IU/kg food). At the end of 6 weeks, the rats were examined for weight gain or loss, general body condition, and cataracts. At sacrifice, blood was collected for measurement of serum glucose, and gamma-crystallin levels were measured in aqueous and vitreous humors using a radioimmunoassay. One lens was homogenized in 8 M guanidinium chloride for ATP analysis. In normal rats, gamma-crystallin was detected in both aqueous and vitreous humors, with the higher concentration in the vitreous humor. Diabetes caused a sixfold increase in gamma-crystallin in both the aqueous and vitreous humors. Diabetes also led to a significant worsening in general body condition, loss of body weight, formation of cataracts, and decrease in lens ATP levels. Addition of vitamin E and vitamin E succinate, but not vitamin E acetate, to the diet resulted in reduction of gamma-crystallin leakage into the vitreous humors and an increase in body weight. There was no improvement noted for the lens ATP levels, the general body condition, or visual cataract score. Neither streptozotocin-induced diabetes nor vitamin E in the diet appeared to affect the weight of the lenses.
Trevithick
J R
JR
Department of Biochemistry, University of Western Ontario, London, Canada.
Linklater
H A
HA
Mitton
K P
KP
Dzialoszynski
T
T
Sanford
S E
SE
D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight; D002386:Cataract / Q000378:metabolism / Q000517:prevention & control*; D003459:Crystallins / Q000378:metabolism*; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000378:metabolism*; D007908:Lens, Crystalline / Q000378:metabolism*; D051381:Rats; D024505:Tocopherols; D014810:Vitamin E / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use*; D014822:Vitreous Body / Q000378:metabolism; D024502:alpha-Tocopherol / Q000031:analogs & derivatives*
D001786:Blood Glucose; D003459:Crystallins; D014810:Vitamin E; D000255:Adenosine Triphosphate; D024502:alpha-Tocopherol; D024505:Tocopherols